72
Participants
Start Date
April 1, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
RSP-1502
RSP-1502 is a sterile, preservative free solution to be administered by inhalation via a nebulizer. Each dose of RSP-1502 contains the active components tobramycin (300 mg) and CaEDTA in a 5 mL solution.
Tobramycin inhalation solution
Tobramycin inhalation solution is 300 mg tobramycin in 5 mL solution.
RECRUITING
Columbia University Cystic Fibrosis Program, New York
RECRUITING
University of Pennsylvania, Philadelphia
RECRUITING
Augusta University, Augusta
RECRUITING
Nationwide Children's Hospital, Columbus
RECRUITING
Rainbow Babies and Children's Hospital / University Hospitals Cleveland Medical Center, Cleveland
RECRUITING
The Minnesota Cystic Fibrosis Center, Minneapolis
RECRUITING
Washington University School of Medicine, St Louis
RECRUITING
Tulane University, New Orleans
RECRUITING
Dell Children's Medical Center of Central Texas, Austin
RECRUITING
Tucson Cystic Fibrosis Center, Tucson
RECRUITING
Center for Cystic Fibrosis at Keck Medical Center of USC, Los Angeles
RECRUITING
Stanford University Medical Center, Palo Alto
RECRUITING
Royal Prince Albert Hospital, Camperdown
RECRUITING
Westmead Hospital, Westmead
RECRUITING
Queensland Children's Hospital, Brisbane
RECRUITING
The Prince Charles Hospital, Brisbane
RECRUITING
Royal Adelaide Hospital, Adelaide
RECRUITING
The Alfred Hospital, Melbourne
RECRUITING
The Royal Children's Hospital, Parkville
RECRUITING
Lung Institute of Western Australia, Nedlands
RECRUITING
The Kids Research Institute Australia, Perth Children's Hospital, Perth
Respirion Pharmaceuticals Pty Ltd
INDUSTRY